ESTRO Multidisciplinary Management of Breast Cancer 2017

Summary 2

• Despite the costs:

• Margin negativity remains the gold standard.

• Increased mastectomy rates • Increased costs • Inferior cosmesis • Additional technical costs (margin probes) • Patient distress